Catalyst Biosciences (CBIO) Given a $19.00 Price Target by B. Riley Analysts
Catalyst Biosciences (NASDAQ:CBIO) has been given a $19.00 price target by stock analysts at B. Riley in a research report issued on Monday. The brokerage currently has a “buy” rating on the biopharmaceutical company’s stock. B. Riley’s price objective would suggest a potential upside of 81.12% from the company’s previous close.
Separately, Zacks Investment Research raised shares of Catalyst Biosciences from a “hold” rating to a “buy” rating and set a $5.25 price objective on the stock in a research report on Wednesday, November 8th.
Catalyst Biosciences (CBIO) traded up $0.56 on Monday, reaching $10.49. 376,700 shares of the company traded hands, compared to its average volume of 461,073. Catalyst Biosciences has a 1-year low of $3.11 and a 1-year high of $18.88.
A number of hedge funds have recently modified their holdings of CBIO. Bank of New York Mellon Corp acquired a new stake in Catalyst Biosciences in the 2nd quarter valued at $107,000. Vanguard Group Inc. increased its stake in shares of Catalyst Biosciences by 294.1% during the 2nd quarter. Vanguard Group Inc. now owns 43,714 shares of the biopharmaceutical company’s stock worth $204,000 after purchasing an additional 32,621 shares during the last quarter. Virtu KCG Holdings LLC acquired a new position in shares of Catalyst Biosciences during the 2nd quarter worth about $103,000. Dimensional Fund Advisors LP acquired a new position in shares of Catalyst Biosciences during the 2nd quarter worth about $372,000. Finally, Zacks Investment Management acquired a new position in shares of Catalyst Biosciences during the 2nd quarter worth about $147,000. Hedge funds and other institutional investors own 31.47% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This report was originally posted by Daily Political and is the sole property of of Daily Political. If you are accessing this report on another domain, it was illegally copied and reposted in violation of US & international copyright & trademark law. The correct version of this report can be accessed at https://www.dailypolitical.com/2017/12/18/catalyst-biosciences-cbio-given-a-19-00-price-target-by-b-riley-analysts.html.
Catalyst Biosciences Company Profile
Catalyst Biosciences, Inc, formerly Targacept, Inc, is a clinical-stage biopharmaceutical company. The Company is focused on creating and developing medicines to address serious medical conditions. The Company focuses its product development efforts in the fields of hemostasis, including the treatment of hemophilia and surgical bleeding, and inflammation, including prevention of delayed graft function (DGF) in renal transplants and the treatment of dry age-related macular degeneration (dry AMD), a condition that can cause visual impairment or blindness.
Receive News & Ratings for Catalyst Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.